Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01212276 · ClinicalTrials.gov registry record · Phase 1
A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma
A Phase 1 study, sponsored by Morphotek.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01212276 is a Phase 1 study that was terminated before completion, run by Morphotek. The registered enrollment target is 18 participants.
The verdict
NCT01212276, a Phase 1 study, was terminated before completion, sponsored by Morphotek.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether therapy with MORAb-028 is safe, effective, and to determine the appropriate dose of MORAb-028 in the treatment of metastatic melanoma.
Interventions
- DRUG MORAb-028
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01212276
The ClinicalTrials.gov registry entry for NCT01212276 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Morphotek, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MORAb-028 is the first listed.
NCT01212276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01212276 about?
NCT01212276 is a clinical study titled "A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma". The purpose of this study is to evaluate whether therapy with MORAb-028 is safe, effective, and to determine the appropriate dose of MORAb-028 in the treatment of metastatic melanoma.
What is the current status of trial NCT01212276?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2010-12. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01212276?
The interventions under investigation include: MORAb-028 (DRUG).
Who is sponsoring clinical trial NCT01212276?
This trial is sponsored by Morphotek, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.